Barr To Extend Branded Business Beyond Women's Health; Urology May Be Next
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has two urology products in development but does not expect either to be approved before mid-2007. Barr is also considering expansion into rheumatology, dermatology, transplantation and vaccines.
You may also be interested in...
Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement
Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor
Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement
Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor
Generic Biologics Provide Significant Growth Opportunity, Barr Says
Barr plans to limit its biotech projects to four until a regulatory pathway for follow-on biologics is established, CEO Downey says. The generic industry is arguing for “common sense” rules, he asserts.